Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics, Inc. reports company developments for a commercial-stage medical technology and healthcare business centered on neurohealth therapies. Its recurring updates cover the NeuroStar Advanced Therapy System, a transcranial magnetic stimulation platform cleared by the U.S. Food and Drug Administration for adults with major depressive disorder, adjunctive use in obsessive-compulsive disorder, anxious depression symptoms in adults with MDD, and first-line adjunctive treatment of MDD in adolescent patients aged 15-21.
News about STIM also covers operating results, U.S. and international system revenue, clinic services added through the completed Greenbrook acquisition, SPRAVATO-related clinic activity, executive and board changes, inducement equity awards, shareholder engagement, and cost-structure actions.
Neuronetics (NASDAQ: STIM) reported Q2 2022 revenue of $16.3 million, exceeding guidance of $15.0 million to $16.0 million. This marks a 15% increase from Q2 2021, driven by a 70% rise in NeuroStar System sales, achieving a record 59 systems sold. Operationally, the company secured FDA clearance for treating OCD and anxious depression, and forged a long-term partnership with Alleviant Health Centers. However, net loss rose to $10.4 million, and international revenues fell by 50%. For 2022, revenue guidance is set between $60.0 million and $62.0 million.
MALVERN, Pa., July 28, 2022 - Neuronetics (NASDAQ: STIM), a medical technology company, will present at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 11:30 am ET. CEO Keith Sullivan and CFO Steve Furlong will lead the presentation, which will be available via a live audio webcast on the company's investor relations page. Neuronetics, known for its NeuroStar® Advanced Therapy system, specializes in treatments for neurological disorders and aims to enhance life quality for patients with mental health conditions through innovative, FDA-cleared solutions.
Neuronetics (NASDAQ: STIM) announced a partnership with Alleviant Health Centers to expand access to its NeuroStar Advanced Therapy for mental health. This agreement makes Neuronetics the exclusive supplier of transcranial magnetic stimulation (TMS) equipment to Alleviant, with six NeuroStar systems to be delivered in 2022. NeuroStar, a proven non-drug treatment for major depressive disorder (MDD), has delivered over 4.5 million treatments with an 83% response rate. Alleviant aims to enhance patient care by upgrading its TMS devices, highlighting the synergy in improving mental health treatment.
MALVERN, Pa., July 19, 2022 (GLOBE NEWSWIRE) -- Neuronetics, focused on neurohealth disorders, will release its second quarter 2022 financial results before market open on August 2, 2022. A conference call to discuss the results will take place at 8:30 a.m. Eastern Time, accessible via webcast. Neuronetics is a leader in TMS therapy, with over 4.3 million treatments delivered for major depressive disorder. Their NeuroStar® system is FDA-cleared and emphasizes the importance of mental health, aiming to improve patients' quality of life.
Summary not available.
Neuronetics, Inc. (NASDAQ: STIM), a leader in non-invasive medical technology for neurological disorders, has announced that CEO Keith Sullivan and CFO Steve Furlong will present at the William Blair 42nd Annual Growth Stock Conference on June 8, 2022, at 2:20 PM ET. The presentation will be accessible via a live audio webcast on the company's investor relations website, with a replay available for 90 days. Neuronetics is renowned for its NeuroStar® Advanced Therapy, a leading TMS treatment for depression, with over 4.3 million procedures performed to date.
Neuronetics, Inc. (NASDAQ: STIM) has published a new peer-reviewed paper in Brain Stimulation Journal, analyzing outcomes from the largest depression registry. The study evaluated 3,871 patients with Major Depressive Disorder (MDD) who underwent Transcranial Magnetic Stimulation (TMS) using High Frequency Left Unilateral (HF-LUL) or Sequential Bilateral (SBL) protocols. Findings revealed that both treatment approaches were effective, with no significant advantage for SBL over HF-LUL. Additionally, the study highlighted that treatment order in SBL affects outcomes.
Neuronetics, a medical technology company, reported strong Q1 2022 results with revenues of $14.2 million, exceeding guidance. This marks a 15% increase year-over-year, driven by a 108% increase in NeuroStar System revenue. Notable achievements include FDA clearance for treating Obsessive-Compulsive Disorder and long-term partnerships with Greenbrook TMS and Transformations Care Network.
Despite the growth, the company faced challenges, including a net loss of $10.8 million and a decrease in treatment session revenue by 2%. They expect full-year revenue between $58.0 million and $62.0 million.
Neuronetics, Inc. (NASDAQ: STIM) has announced an extended commercial partnership with Transformations Care Network, enhancing access to NeuroStar systems, which provide transcranial magnetic stimulation (TMS) for mental health treatment. The partnership aims to support the growing number of Americans facing mental health disorders, facilitating better patient access to care. Neuronetics, a leader in TMS technology, emphasizes its commitment to improving quality of life through non-invasive treatment options backed by extensive clinical research.
Neuronetics (NASDAQ: STIM) announced its participation as the only Platinum Sponsor at the Clinical TMS Society Annual Meeting in Chicago from May 12-14, 2022. The company will present new findings from the NeuroStar Outcomes Registry, the largest depression outcomes registry globally. Key discussions include the impact of transcranial magnetic stimulation (TMS) on reducing anxiety in patients with major depressive disorder. Additionally, NeuroStar has recently received FDA clearance for its TMS therapy as an adjunct treatment for Obsessive-Compulsive Disorder (OCD).